About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker BMRN · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human…
NCT06668805 · Noonan Syndrome
Vosoritide Injection
BMRN
BioMarin Pharmaceutical
Phase 2Terminated
was active, not recruiting
18Sep 16, 2026Registry ↗
Nov 12, 2026Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
NCT06455059 · Hypochondroplasia
Vosoritide, Placebo
BMRN
BioMarin Pharmaceutical
Phase 3Completed
was active, not recruiting
81Apr 23, 2026Registry ↗
Nov 10, 2026Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
NCT07477691 · Phenylketonuria
Pegvaliase, Methotrexate
BMRN
BioMarin Pharmaceutical
Phase 4Recruiting12Sep 30, 2027Registry ↗
Oct 22, 2026Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondropla…
NCT07441876 · Achondroplasia
BMN 333, Vosoritide Injection [Voxzogo]
BMRN
BioMarin Pharmaceutical
Phase 2/3Recruiting160Jun 2029Registry ↗
Oct 1, 2026Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
NCT06780332 · Phenylketonuria, PKU
RDD to Palynziq
BMRN
BioMarin Pharmaceutical
Phase 4Completed9Aug 17, 2026Registry ↗
Sep 9, 2026Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
NCT07073014 · Hypochondroplasia
Vosoritide
BMRN
BioMarin Pharmaceutical
Phase 3Enrolling by invitation140Oct 2044Registry ↗
Jul 24, 2026An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participa…
NCT07573631 · Duchenne Muscular Dystrophy (DMD)
BMN 351
BMRN
BioMarin Pharmaceutical
Phase 2Enrolling by invitation18Dec 2031Registry ↗
Jul 21, 2026Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketo…
NCT05270837 · Phenylketonuria (PKU)
Pegvaliase, Diet Only
BMRN
BioMarin Pharmaceutical
Phase 3Active, not recruiting55Jan 14, 2025Registry ↗
Jul 10, 2026Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active…
NCT04684940 · Hemophilia A With Inhibitor, Hemophilia A With Anti Factor…
Valoctocogene roxaparvovec
BMRN
BioMarin Pharmaceutical
Phase 1/2Completed10Apr 20, 2026Registry ↗
Jun 30, 2026VIrtual STudy in Achondroplasia for the US (VISTA)
NCT06168201 · Achondroplasia
BMRN
BioMarin Pharmaceutical
—Recruiting170Feb 2028Registry ↗
Jun 30, 2026Cerliponase Alfa Observational Study in the US
NCT04476862 · Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Cerliponase Alfa, Administration Kit
BMRN
BioMarin Pharmaceutical
—Active, not recruiting35Aug 31, 2030Registry ↗
Jun 25, 2026A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN…
NCT06280209 · Duchenne Muscular Dystrophy
BMN 351
BMRN
BioMarin Pharmaceutical
Phase 1/2Active, not recruiting18Apr 14, 2027Registry ↗
Jun 23, 2026A Study to Assess Growth in Children With Idiopathic Short Stature
NCT06309979 · Idiopathic Short Stature
BMRN
BioMarin Pharmaceutical
—Recruiting300Dec 31, 2040Registry ↗
May 22, 2026A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
NCT06382155 · Idiopathic Short Stature
Vosoritide Injection, Human Growth Hormone
BMRN
BioMarin Pharmaceutical
Phase 2Recruiting100Jun 2026Registry ↗
May 6, 2026Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
NCT06738017 · Alpha 1-Antitrypsin Deficiency
BMN 349, Placebo
BMRN
BioMarin Pharmaceutical
Phase 1Active, not recruiting6Aug 19, 2026Registry ↗
Mar 31, 2026A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262 · Hypochondroplasia
Vosoritide, Placebo
BMRN
BioMarin Pharmaceutical
Phase 2Recruiting60Jun 30, 2028Registry ↗
Mar 25, 2026A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
NCT05813678 · Phenylketonuria (PKU)
Pegvaliase
BMRN
BioMarin Pharmaceutical
—Recruiting450Nov 1, 2033Registry ↗
Mar 24, 2026A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for P…
NCT06305234 · Phenylketonuria (PKU)
Pegvaliase
BMRN
BioMarin Pharmaceutical
—Recruiting200Nov 18, 2033Registry ↗
Mar 24, 2026A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq®…
NCT05579548 · Phenylketonuria, Maternal
Pegvaliase
BMRN
BioMarin Pharmaceutical
—Recruiting50Oct 4, 2032Registry ↗
Mar 19, 2026Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
NCT06224907 · Hemophilia A
Valoctocogene roxaparvovec
BMRN
BioMarin Pharmaceutical
Phase 3Active, not recruiting6Apr 16, 2025Registry ↗
Mar 13, 2026A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
NCT04554940 · Achondroplasia
vosoritide
BMRN
BioMarin Pharmaceutical
Phase 2Active, not recruiting20Dec 2027Registry ↗
Mar 13, 2026An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
NCT03989947 · Achondroplasia
Active BMN 111: Subcutaneous injection of recommended dose…
BMRN
BioMarin Pharmaceutical
Phase 2Active, not recruiting73May 2038Registry ↗
Mar 13, 2026An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
NCT03424018 · Achondroplasia
BMN 111
BMRN
BioMarin Pharmaceutical
Phase 3Active, not recruiting119Jun 2031Registry ↗
Mar 13, 2026A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondro…
NCT02724228 · Achondroplasia
BMN 111
BMRN
BioMarin Pharmaceutical
Phase 2Active, not recruiting30Dec 2027Registry ↗
Jan 12, 2026A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMari…
NCT05768386 · Hemophilia A
BMRN
BioMarin Pharmaceutical
—Enrolling by invitation172Jan 2040Registry ↗
Oct 8, 2025Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids…
NCT04323098 · Hemophilia A
valoctocogene roxaparvovec
BMRN
BioMarin Pharmaceutical
Phase 3Completed22Jan 27, 2023Registry ↗
Aug 22, 2025Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5
NCT03520712 · Hemophilia A, Gene Therapy
Valoctocogene Roxaparvovec
BMRN
BioMarin Pharmaceutical
Phase 1/2Terminated3Aug 7, 2024Registry ↗
Apr 10, 2025Gene Therapy Study in Severe Haemophilia A Patients (270-201)
NCT02576795 · Severe Haemophilia A
valoctocogene roxaparvovec
BMRN
BioMarin Pharmaceutical
Phase 1/2Completed15Feb 14, 2024Registry ↗
Apr 3, 2025A Multicenter Multinational Observational Study of Children With Hypochondroplasia
NCT06212947 · Hypochondroplasia
BMRN
BioMarin Pharmaceutical
—Recruiting400Dec 31, 2043Registry ↗
Mar 25, 2025Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A…
NCT03370913 · Hemophilia A
valoctocogene roxaparvovec
BMRN
BioMarin Pharmaceutical
Phase 3Completed144Nov 16, 2020Registry ↗
Feb 17, 2025A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With…
NCT02678689 · Jansky-Bielschowsky Disease, Batten Disease
BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1),…
BMRN
BioMarin Pharmaceutical
Phase 2Completed14Apr 20, 2022Registry ↗
Dec 12, 2024AAV Gene Therapy Study for Subjects with PKU
NCT04480567 · Phenylketonuria (PKU)
BMN 307
BMRN
BioMarin Pharmaceutical
Phase 1/2Active, not recruiting100Dec 2027Registry ↗
Aug 19, 2024A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associ…
NCT05580692 · Hemophilia A
Biospecimen Collection
BMRN
BioMarin Pharmaceutical
Not applicableTerminated321Jul 31, 2024Registry ↗
Jun 13, 2024A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With…
NCT03583697 · Achondroplasia
BMN 111, Placebo
BMRN
BioMarin Pharmaceutical
Phase 2Completed75Jan 26, 2022Registry ↗
Jun 11, 2024A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
NCT06138327 · Hyperoxaluria, Nonalcoholic Fatty Liver Disease
BMN 255, Placebo
BMRN
BioMarin Pharmaceutical
Phase 1Withdrawn0Mar 25, 2024Registry ↗
May 16, 2024A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
NCT05121376 · Hereditary Angioedema, HAE
Dose 1 of BMN 331, Dose 2 of BMN 331
BMRN
BioMarin Pharmaceutical
Phase 1/2Active, not recruiting44Nov 2028Registry ↗
Apr 24, 2024A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV)…
NCT04560933 · Hemophilia A
Blood sample collection
BMRN
BioMarin Pharmaceutical
—Completed186Sep 20, 2023Registry ↗
Mar 5, 2024A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
NCT02294877 · Mucopolysaccharidosis IV Type A, Morquio A Syndrome
Vimizim® (elosulfase alfa)
BMRN
BioMarin Pharmaceutical
—Completed418Feb 21, 2024Registry ↗
Oct 12, 2023Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants
NCT05813314 · Achondroplasia
BMN 111 administration via Injector Pen, BMN 111 administra…
BMRN
BioMarin Pharmaceutical
Phase 1Terminated36Jun 14, 2023Registry ↗
Oct 3, 2023Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A…
NCT03392974 · Hemophilia A
Valoctocogene Roxaparvovec
BMRN
BioMarin Pharmaceutical
Phase 3Completed1May 22, 2019Registry ↗
Apr 24, 2023Kuvan®'s Effect on the Cognition of Children With Phenylketonuria
NCT01965912 · Phenylketonuria
Kuvan®
BMRN
BioMarin Pharmaceutical
Phase 4Completed34Jan 4, 2023Registry ↗
Mar 14, 2023A Prospective Clinical Study of Phenylketonuria (PKU)
NCT04452513 · Phenylketonurias
BMRN
BioMarin Pharmaceutical
—Completed32Jun 2, 2022Registry ↗
Jan 9, 2023A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)
NCT02191917 · Late-onset Pompe Disease
Respiratory muscle strength measurements by different techn…
BMRN
BioMarin Pharmaceutical
—Terminated8Jun 22, 2016Registry ↗
Oct 12, 2022PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry
NCT00778206 · Phenylketonuria, Hyperphenylalaninaemia
Kuvan
BMRN
BioMarin Pharmaceutical
—Completed1,887Jan 29, 2021Registry ↗
Aug 24, 2022An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 D…
NCT02485899 · Jansky-Bielschowsky Disease, Batten Disease
BMN 190, Intracerebroventricular (ICV) access device
BMRN
BioMarin Pharmaceutical
Phase 1/2Completed23Dec 10, 2020Registry ↗
Apr 15, 2022Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalanine…
NCT01016392 · Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or…
BMRN
BioMarin Pharmaceutical
—Completed627May 31, 2021Registry ↗
Mar 2, 2022A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
NCT03197766 · Achondroplasia
BMN 111, Placebo
BMRN
BioMarin Pharmaceutical
Phase 3Completed121Oct 30, 2019Registry ↗
Feb 17, 2022Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With P…
NCT03694353 · Phenylketonuria (PKU)
Pegvaliase
BMRN
BioMarin Pharmaceutical
Phase 3Completed37Jan 13, 2021Registry ↗
Oct 12, 2021Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)
NCT00924703 · Phenylketonuria
rAvPAL-PEG
BMRN
BioMarin Pharmaceutical
Phase 2Completed68Jan 31, 2019Registry ↗
Jul 23, 2021A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adul…
NCT00789568 · Phenylketonuria
sapropterin dihydrochloride, Moxifloxacin
BMRN
BioMarin Pharmaceutical
Phase 1Completed56Jan 2009Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:25 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances